筑波大学Mamiko Sakata-Yanagimoto团队在研究中取得进展。他们揭示了不同的滤泡T细胞亚群调节淋巴瘤的进展和结果。2025年7月3日，国际知名学术期刊《癌细胞》发表了这一成果。

小组对滤泡T细胞进行了多组学分析，利用泛癌症单细胞图谱、空间分辨单细胞转录组学和多重蛋白谱，以及功能表征。研究人员确定了转录和空间上不同的非TFH滤泡T细胞亚群在FL中扩增。这些亚群表现出增强的抗肿瘤特性，并形成独特的空间生态位。它们的表型在白细胞介素-21优势条件下被复制，揭示了产生这些亚群的离散自我调节细胞生态系统，并可能是FL临床行为的基础。

此外，这些亚群独立于现有的预后标志物，对FL的预后进行了分类。他们的发现强调了以前未被认识到的免疫，可以促进他们对淋巴瘤的理解并改善患者管理。

据悉，滤泡性淋巴瘤（FL）的特征是肿瘤滤泡结构的扩张，并被认为具有独特形式的T细胞免疫。然而，滤泡T细胞在滤泡辅助T细胞（TFH）细胞之外的异质性和作用在很大程度上仍未被探索。

附：英文原文

Title: Distinct follicular T cell subsets regulate lymphoma progression and outcomes

Author: Yoshiaki Abe, Junko Zenkoh, Akinori Kanai, Daisuke Ikeda, Daisuke Kaji, Aya Sawa, Ryota Matsuoka, Kei Asayama, Rikako Tabata, Ryota Ishii, Manabu Fujisawa, Kenichi Makishima, Sakurako Suma, Yasuhito Suehara, Keiichiro Hattori, Tatsuhiro Sakamoto, Hidekazu Nishikii, Chikashi Yoshida, Hiroko Bando, Ayako Suzuki, Yasunori Ota, Yoshihito Otsuka, Daisuke Matsubara, Kosei Matsue, Shigeru Chiba, Christian Steidl, Yutaka Suzuki, Mamiko Sakata-Yanagimoto

Issue&Volume: 2025-07-03

Abstract: Follicular lymphoma (FL) is characterized by the expansion of neoplastic follicle structures and is suggested to have a distinctive form of T cell immunity. However, the heterogeneity and role of follicular T cells beyond T follicular helper (TFH) cells remain largely unexplored in FL. Here, we performed multi-omics analyses of follicular T cells in FL leveraging pan-cancer single-cell mapping, spatially resolved single-cell transcriptomics and multiplex protein profiling, and functional characterization. We identified transcriptionally and spatially distinct non-TFH follicular T cell subsets that expand in FL. These subsets exhibit enhanced anti-tumorigenic properties and form unique spatial niches. Their phenotypes were replicated under interleukin-21–predominant conditions, revealing discrete self-regulatory cellular ecosystems that generate these subsets and may underlie FL clinical behaviors. Furthermore, these subsets robustly stratify FL prognoses, independently of existing prognostic markers. Our findings highlight previously unrecognized immunity that could advance our understanding of lymphoma and improve patient management.

DOI: 10.1016/j.ccell.2025.06.013

Source: https://www.cell.com/cancer-cell/abstract/S1535-6108(25)00263-6